Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625412 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT05625412 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 70 participants.
The verdict
NCT05625412, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
- DRUG Nivolumab
- DRUG BMS-986360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-12-09 |
| Est. Completion | 2025-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625412
The ClinicalTrials.gov registry entry for NCT05625412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT05625412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05625412 about?
NCT05625412 is a clinical study titled "A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors". The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.
What is the current status of trial NCT05625412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2022-12-09. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT05625412?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG), Nivolumab (DRUG), BMS-986360 (DRUG).
Who is sponsoring clinical trial NCT05625412?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.